Literature DB >> 26970464

Does effect of BCG vaccine decrease with time since vaccination and increase tuberculin skin test reaction?

R Subramani1, Manjula Datta2, S Swaminathan3.   

Abstract

The protective efficacy of BCG was studied for over 15 years, from 1968, in South India. A secondary analysis of data was performed to investigate the relationship between Bacille Calmette-Guérin (BCG) and tuberculosis (TB) disease and between BCG and positive tuberculin skin test for different time periods among children aged less than 10 years. A randomized controlled trial was conducted, where 281,161 persons were allocated to receive BCG 0.1mg, BCG 0.01mg or placebo. Tuberculin skin test was performed at baseline and at 4 years after BCG vaccination. Surveys were conducted every 2.5 years to detect all new cases of culture-positive/smear-positive TB occurring in the community over a 15-year period. Relative risk (RR) was obtained from the ratio of incidence among the vaccinated and the placebo groups. Among those children vaccinated with 0.1mg of BCG, the RR for TB was 0.56 (95% CI: 0.32-0.87, P=0.01) at 12.5 years but increased to 0.73 later. Similar pattern was seen with 0.01mg. The increase in the number of skin test positives with 0.1mg of BCG was 57.8%, 49.4% and 34% for cut-off points at ≥10mm, ≥12mm and ≥15mm, respectively. The study suggests that the effect of BCG may decrease since vaccination and the tuberculin positive was higher at post-vaccination test period due to BCG.
Copyright © 2015 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BCG vaccine; Protective efficacy; Relative risk; Tuberculin skin test; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 26970464     DOI: 10.1016/j.ijtb.2015.08.002

Source DB:  PubMed          Journal:  Indian J Tuberc        ISSN: 0019-5707


  3 in total

1.  Tuberculosis in children with sickle cell anaemia: a retrospective study in French tertiary care centres.

Authors:  Nina Droz; Agathe De Lauzanne; Laurent Holvoet; Florence Missud; Malika Benkerrou; Valentine Brousse; Marie-Hélène Odièvre; Albert Faye; Berengere Koehl
Journal:  Eur J Pediatr       Date:  2017-04-11       Impact factor: 3.183

2.  Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70.

Authors:  Fu-Ying Dai; Jun-Fang Wang; Xue-Li Gong; Lang Bao
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

3.  Re: The Bacillus Calmette-Guerin (BCG) Vaccine: Is it a better choice for the treatment of viral warts?

Authors:  Mahmood D Al-Mendalawi
Journal:  Sultan Qaboos Univ Med J       Date:  2021-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.